Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 4/20 | 0.81 |
| ▸ | BRD4 | O60885 | 3/20 | 0.81 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PTGIR | P43119 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927248 | 0.86 | CREBBP (0.93) | CREBBPBRD4 | |
| SCHEMBL4736108 | 0.82 | BRD4 (0.73) | CREBBPBRD4PTGIR | |
| SCHEMBL4919399 | 0.80 | BRD4 (0.70) | CREBBPBRD4CNR2 | |
| SCHEMBL4923459 | 0.80 | BRD4 (0.70) | CREBBPBRD4CNR2 | |
| SCHEMBL4926209 | 0.80 | BRD4 (0.65) | CREBBPBRD4AVPR1BCNR2 | |
| SCHEMBL4929940 | 0.77 | BRD4 (0.66) | CREBBPBRD4KDM2BKMT2ACNR2 | |
| SCHEMBL4928449 | 0.75 | BRD4 (0.63) | CREBBPBRD4CNR2 | |
| SCHEMBL14113972 | 0.74 | BRD4 (0.62) | CREBBPBRD4CNR2 | |
| SCHEMBL4925458 | 0.74 | CREBBP (0.71) | CREBBPBRD4PTGIRPDE4BKDM2B | |
| SCHEMBL4925636 | 0.72 | CREBBP (0.68) | CREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079316-A1 | TETRAHYDROQUINOLINONES, TETRAHYDRONAPHTHYRIDONES AND DERIVATIVES THEREOF | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CNR1, CNR2, TRPV1 | CREBBP 3109/4885BRD4 407/4885AVPR1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.